A subretinal injection of ATSN-201 gene therapy demonstrated promising results in patients with X-linked retinoschisis in a phase 1/2 clinical trial, according to a press release from Atsena Therapeutics.
Part A of the LIGHTHOUSE study evaluated the tolerability and safety of three doses of ATSN-201, which uses the company’s AAV.SPR spreading capsid to create therapeutic levels of gene expression in photoreceptors in the central retina, the release said.
“The interim results from the study indicate that ATSN-201 can be safely delivered subretinally to patients with XLRS,”